1. Scrip
  2. >>Therapy Areas

Theravance ends ADHD program for TD-9855

 
• By Mandy Jackson

Theravance CEO Rick Winningham said during a presentation at the Credit Suisse Annual Health Care Conference in Scottsdale, Arizona on 13 November that the company will discontinue development of TD-9855 in the treatment of attention-deficit/hyperactivity disorder (ADHD), because the drug did not meet the primary efficacy endpoint in a placebo-controlled Phase II clinical trial.

Theravance CEO Rick Winningham said during a presentation at the Credit Suisse Annual Health Care Conference in Scottsdale, Arizona on 13 November that the company will discontinue development of TD-9855 in the treatment of attention-deficit/hyperactivity disorder (ADHD), because the drug did not meet the primary efficacy endpoint in a placebo-controlled Phase II clinical trial.

South San Francisco-based Theravance reported Mr Winningham's comments on TD-9855 disclosure in a US Securities and Exchange Commission (SEC) filing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.